5TH ANNUAL RALLY WILL BE HELD SEPT 22TH, 2012
5th ANNUAL RALLY FOR ALI
IN SEARCH OF A CURE FOR DIABETES
ALL DONATIONS WILL GO TO HARVARD STEM CELL INSTITUTE
PICNIC FOR A CAUSE
KRAUSE’S GROVE, 2 Beach Road, Halfmoon, NY
SATURDAY, SEPTEMBER 21, 2013
1:00 PM TO 6:00 PM ~ RAIN OR SHINE
$30.00 per adult ticket at gate - $20.00 for children under 12
includes donation to Harvard Stem Cell Institute.
5 hour picnic with soda, beer, games, raffles, 50/50, live music
JAMBONE - THE BEAR BONES PROJECT - BLUE HAND LUKE
SPECIAL GUEST APPEARANCE BY AWARD-WINNING IRISH STEP DANCER
GRACE CATHERINE MOMROW (Ali’s cousin)
Abundant food and dessert being served 1:00 p.m. to 5:00 p.m.
Those who wish to join a pre-picnic motorcycle cavalcade around the beautiful Tomhannock Reservoir in Ali’s honor will meet at the Troy Plaza on Hoosick Street at 10:00 A.M. for sign up and the cavalcade will kick off at 11:00 A.M. sharp.
For more info: https://www.facebook.com/Rally4Ali
For Further Information
For the Run, Wally Urzan
For the Picnic & Cause
Monday, March 29, 2010
At Rutgers’ Stem Cell Research Center scientists are exploring the mysteries of human embryonic stem cells and their potential use in treating diseases, repairing damaged organs and drug development. Center staff also offer a course in proper lab techniques in working with stem cells. The center was established with a grant to Professors Martin Grumet and Wise Young from the State of New Jersey through its Commission on Science and Technology.
The center focuses on human embryonic stem cells, known as hESCs, because they are pluripotent, meaning they have the unique ability to develop into any kind of cell in the body – whether it is a heart cell or a brain cell or a liver cell.
Among the accomplishments of the Rutgers Stem Cell Research Center (RSCRC) is a series of recently published papers, one of which is by Professor Rick Cohen and his colleagues, describing the derivation of New Jersey’s first hESC lines.
A stem cell line is a family of constantly dividing cells, the product of a single parent stem cell. The new lines are particularly important. Many of the cell lines previously approved by the federal government were found to have been contaminated with non-human proteins that compromise their potential therapeutic use in human subjects.
In his stem cell course, Professor Rick Cohen teaches students from Hoffmann-La Roche, Inc. and City College of New York.
The paper also describes how the team developed a series of tests to determine the quality of these new cell lines. This quality control approach is critical to ensure that the cells are suitable for laboratory use and potential clinical applications. For example, among the panel of 11 assays is a test to make certain cells are still completely pluripotent.
Another test included in the paper ensures that the cells are not contaminated with common human viruses. These might include HIV, the virus that causes AIDS; the herpes simplex virus, which causes cold sores; and the human papilloma virus, now believed to be a leading cause of cervical cancer in adult women.
Research Associate Jennifer Moore, the lead author on the paper, noted that the cells’ chromosome complement is also tested for abnormality. Human cells normally have 23 chromosomes, but mutations in hESCs are known to appear as duplications of chromosomes 12 and 17. “This doesn’t happen often but it is not a rare event,” Moore said. “Duplications could affect stem cell functions potentially precluding their clinical use.”
(left) Maha Mahadevan (University of Arkansas for Medical Sciences) receives guidance from Jennifer Moore while a Rutgers student works with Stem Cell Technologies guest instructor Debbie King (standing).
The RSCRC is also active in training new stem cell scientists through the Stem Cell Training Course developed by Cohen. It consists of one week of intensive instruction and workshops from 8 a.m. to 5 p.m. daily and covers the growth, maintenance, and differentiation of human embryonic stem cells. Almost everything one needs to grow human embryonic stem cells is included in the course, which has run eight times and has trained more than 100 scientists. Attendees have included researchers from all over the world from universities, including Rutgers, and the pharmaceutical industry. The value and importance of the training program has been recognized by an invitation from a scientific publishing company to Cohen to prepare a book based on the course.
The research described by Cohen and his associates and the training courses were supported by additional grants from the New Jersey Commission on Science and Technology. The state-supported research also helped build the capacity and credibility of the center, setting the stage for its researchers to win new federal grants. Professors Ron Hart and Grumet have already won major federal grants from the National Institutes of Health.
Sharing staff with its neighbor, the W.M. Keck Center for Collaborative Neuroscience, about 30 individuals at any given time are working in the RSCRC.
Friday, March 26, 2010
Entest BioMedical Inc. (OTCBB: ENTB) announced today that Chairman & CEO David Koos, along with Lead Inventor Dr. Steven Josephs, provided clarification on the Company's new patent application for use of chemokines in its stem cell / photoceutical therapy for treatment of Chronic Obstructive Pulmonary Disease (COPD) during the Company's weekly blogcast held March 23, 2010.
Dr. Josephs noted, "Chemokines are naturally produced in the body during times of injury and are believed to be an essential part of the healing process. These chemokines cause stem cells to 'home' to injured areas. It is our belief the addition of chemokines to our COPD treatment model will aid in focusing stem cells towards damaged lung tissue painted by our photoceutical device."
Entest's Chairman & CEO David Koos said, "In its simplest form, our COPD treatment model consists of three components: an alarm clock, a bus for transportation and a GPS navigational system. An FDA approved stem cell mobilizer acts as an alarm clock activating the stem cells. Chemokines serve as the 'bus' transporting the stem cells to a location in the body. The laser serves as a GPS system navigating the bus to the destination -- damaged lung tissue."
The entire blogcast has been archived on the Company's blog site: www.entestbioblog.com.
About Entest BioMedical Inc.:
Entest BioMedical Inc. (OTCBB: ENTB) is involved with the development of stem cell therapy treatments for Chronic Obstructive Pulmonary Disease (COPD), immuno-cancer therapies, testing procedures for diabetes, stem cell research applications for diabetes and other illnesses. The Company also is involved with medical device development (including stem cell extraction instrumentation). ENT-576™ is a proprietary laser device currently under development by Entest. The Company has filed 4 patent applications relating to the treatment of COPD. Entest BioMedical Inc. is a majority owned subsidiary of Bio-Matrix Scientific Group Inc. (OTCBB: BMSN). Recently Entest published in the peer reviewed literature its platform technology, which is available at http://www.translational-medicine.com/content/pdf/1479-5876-7-106.pdf.
This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
Contact: David R. Koos, Chairman & CEO Entest BioMedical Inc. 619.702.1404 Direct 619.330.2328 Fax www.entestbio.com firstname.lastname@example.org
Thursday, March 25, 2010
Wednesday, March 24, 2010
A ten-year-old British boy has become the first child in the world to undergo a revolutionary windpipe transplant, it has been announced.
The landmark operation involved injecting the scaffold of a windpipe, taken from a dead donor, with stem cells from the boy before implanting it in his throat.
The stem cells were removed from the boy’s bone marrow and were ready for use just four hours later.
The cells trigger regrowth to create a normal windpipe without any of the risks of normal transplantation such as the organ being rejected by the body.
The operation took place at Great Ormond Street Hospital, in London, on Monday and the boy is breathing by himself and able to speak normally.